Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
7.81
-0.01 (-0.06%)
Aug 12, 2025, 12:00 PM - Market open
H&E Equipment Services Revenue
Capricor Therapeutics had revenue of $13.39M in the twelve months ending June 30, 2025, down -50.68% year-over-year. In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%.
Revenue (ttm)
$13.39M
Revenue Growth
-50.68%
P/S Ratio
24.66
Revenue / Employee
$83,701
Employees
160
Market Cap
356.98M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CAPR News
- 4 days ago - Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewsWire
- 6 days ago - Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 - GlobeNewsWire
- 11 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewsWire
- 12 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR - PRNewsWire
- 12 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR - GlobeNewsWire
- 13 days ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
- 18 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewsWire
- 25 days ago - BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses - GlobeNewsWire